{"id":529269,"date":"2021-02-08T16:00:01","date_gmt":"2021-02-08T16:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=529269"},"modified":"2021-02-08T16:00:01","modified_gmt":"2021-02-08T16:00:01","slug":"epidermal-growth-factor-receptornon-small-cell-lung-cancer-egfrnsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/epidermal-growth-factor-receptornon-small-cell-lung-cancer-egfrnsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players_529269.html","title":{"rendered":"Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the EGFR NSCLC, historical and forecasted epidemiology as well as the EGFR NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>How has <\/strong><strong>EGFR-NSCLC<\/strong><strong> impacted people&#8217;s lives?<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total incident population of NSCLC in 7MM was <strong>484,726&nbsp; <\/strong>in 2017<\/li>\n<li>The incident cases of EGFR mutation in the United States in 2017 was 37,370<\/li>\n<li>The incident population of EGFR-NSCLC in the United States contributed around <strong>34%<\/strong> of the total population of EGFR mutated NSCLC in the 7MM in 2017<\/li>\n<li>Among the EU5 countries, Germany had the highest incident population of NSCLC, and that was <strong>29%<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>How will Disease transform <\/strong><strong>EGFR-NSCLC<\/strong><strong> Market?&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/a1d7ce5d47e4d5f79ec5ad990d4d763f.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Market Drivers<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Increasing Use of Biomarker Testing<\/li>\n<li>Increase in the Mutation Specific Trials Activity and Approval<\/li>\n<li>Increasing Incidence of NSCLC<\/li>\n<li>Rich Pipeline and label expansion of approved therapies<\/li>\n<li>Cost-Effectiveness of Therapies<\/li>\n<li>Small Patient Populations for Specific Subsets of NSCLC<\/li>\n<li>Generic or Biosimilar Erosion<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Market Barriers<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Cost-Effectiveness of Therapies<\/li>\n<li>Small Patient Populations for Specific Subsets of NSCLC<\/li>\n<li>Generic or Biosimilar Erosion<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market\"><strong>EGFR- NSCLC market size<\/strong><\/a> in 7MMwas <strong>USD 1,893 million i<\/strong>n 2017&rdquo;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market\"><strong>EGFR- NSCLC market size<\/strong><\/a> in 7MMwas <strong>USD 1,893 million i<\/strong>n 2017&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Which biotechnical companies are developing <\/strong><strong>EGFR-NSCLC<\/strong><strong> drugs?&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market\"><strong>EGFR-NSCLC market<\/strong><\/a> is anticipated to change in the coming years owing to the rise in numbers of company&rsquo;s taking interest in the development of drugs for EGFR-NSCLC.<\/p>\n<p style=\"text-align: justify;\">Key players, such as Takeda, Yuhan Corporation\/ Janssen Research &amp; Development, Novartis, Janssen Research &amp; Development, and others are involved in developing drugs for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market\"><strong>EGFR-NSCLC treatment market<\/strong><\/a>.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=epidermal-growth-factor-receptornon-small-cell-lung-cancer-egfrnsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=epidermal-growth-factor-receptornon-small-cell-lung-cancer-egfrnsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the EGFR NSCLC, historical and forecasted epidemiology as well as the EGFR NSCLC market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/epidermal-growth-factor-receptornon-small-cell-lung-cancer-egfrnsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players_529269.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-529269","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/529269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=529269"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/529269\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=529269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=529269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=529269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}